JPMorgan Chase & Co. Reaffirms “Overweight” Rating for Vertex Pharmaceuticals (NASDAQ:VRTX)
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “overweight” rating restated by investment analysts at JPMorgan Chase & Co. in a report issued on Friday, Benzinga reports. They currently have a $560.00 target price on the pharmaceutical company’s stock, up from their prior target price of $515.00. JPMorgan Chase & Co.‘s price target […]
11 Sep 12:42 · The Markets Daily